Efficient synthesis and evaluation of bimodal ligand NETA.

Abstract

The efficient and short synthetic route to the structurally novel bimodal ligand NETA for antibody-targeted radiation therapy (radioimmunotherapy, RIT) of cancer was developed. The structure of NETA was determined by X-ray crystallography. The arsenazo-based UV spectroscopic complexation kinetics data suggest that NETA is a promising chelator for use in RIT applications of (212)Bi, (213)Bi, and (177)Lu.

• Authors: Hyun-Soon Chong, Hyun A Song, Noah Birch, Thien Le, Sooyoun Lim, Xiang Ma
• Journal: Bioorganic & medicinal chemistry letters (Bioorg Med Chem Lett) Vol. 18 Issue 11 Pg. 3436-9 (Jun 01 2008) ISSN: 1464-3405 [Electronic] England
• PMID: 18445528 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• (2-(4,7-biscarboxymethyl(1,4,7)triazacyclonona-1-yl-ethyl)carbonylmethylamino)acetic acid
• (2-(4,7-biscarboxymethyl(1,4,7)triazacyclononan-1-ylethyl)carbonylmethylamino)acetic acid
• Acetates
• Chelating Agents
• Heterocyclic Compounds
• Ligands
• Radioisotopes
• Lutetium
• Bismuth

Topics

• Acetates (chemical synthesis, chemistry, pharmacology)
• Bismuth
• Chelating Agents (chemical synthesis, chemistry, pharmacology)
• Crystallography, X-Ray
• Drug Design
• Heterocyclic Compounds (chemical synthesis, chemistry, pharmacology)
• Kinetics
• Ligands
• Lutetium
• Molecular Conformation
• Molecular Structure
• Radioimmunotherapy
• Radioisotopes